Cosmos Health posted Q2 2026 revenue of $18.99 million, up 28.8% year over year; H1 revenue rose 29.7% to $36.91 million.
Adjusted EBITDA loss widened to $1.13 million in Q2 2026; adjusted gross profit climbed 58% year over year.
Balance sheet and capital actions
Total liabilities fell 13.3% to $40.79 million at June 30, 2026; stockholders’ equity increased 12.2% to $20.67 million.
The company retired an $8 million senior secured convertible note on Aug. 28, 2026, eliminating further conversions, and repurchased 5,112,000 shares for $1.11 million.
Guidance and management commentary
Cosmos Health reaffirmed 2026 revenue guidance above $90 million.
COSM•
